Antibiotics have saved millions of lives Antibiotics are losing their effect.

Slides:



Advertisements
Similar presentations
Environmental Hazards and Human Health
Advertisements

Methicillin resistant Staphylococcus aureus (MRSA) in the Nordic countries Petter Elstrøm Advisor Norwegian Institute of Public Health.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD A report prepared by WHO for the Netherlands Government by Warren Kaplan Richard Laing and Saloni TannaMarjolein.
Attitudes towards antibiotics and Vaccinations amongst year olds years project qualitative results.
| Antimicrobial Resistance: Global Surveillance Global Action Plan to combat antimicrobial resistance.
Antibiotic Stewardship Curriculum Developed by: Vera P. Luther, M.D.
Healthcare Associated Infection and Antimicrobial Resistance Research How is it organised and funded?
MRSA Found in U.S. Wastewater Treatment Plants.  MRSA is a type of staph bacteria that is resistant to certain antibiotics called beta-lactams (Centers.
ARIAtlas.org. Global Impact TB causes nearly two million deaths a year, making it the world’s seventh most common cause of mortality. More than two billion.
Michel Goldman, Executive Director Innovative Medicines Initiative (IMI)
European Antibiotic Awareness Day 2013, 18 November 2013 European Antibiotic Awareness Day 2013 * Joining efforts to avoid a post-antibiotic era [Name.
Discovery and development of antibiotics
Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.
Partnering across borders to effect change Glasgow – 3 June 2013 Jean Georges, Executive Director.
BACTERIA, ANTIBIOTICS AND ANTIBIOTIC RESISTANCE Photo: Mycobacterium tuberculosis bacteria, NIAID (from flickr). 1 Photo: Staphylococcus epidermidis bacteria,
International Epidemics Lecture September 23, 2014 B.W. Cue, Jr. (UMB 1969) Outline – An overview of infectious microbes (excluding fungii) Bacterial vs.
Antimicrobial resistance “One health fits all”
Essential Drugs Programme
| Antimicrobial Resistance Global Report on Surveillance 2014 Global Action Plan to combat antimicrobial resistance.
1 Copyright: W. Michael Scheld, M.D.. 2 Infectious Diseases Society of America (IDSA) – Antimicrobial Availability Task Force (AATF) W. Michael Scheld,
Tuberculosis in the UK 2013 report
Surprising Victories Against Old Foes: New Hope for Prevention and Control of Healthcare- Associated MRSA Infections John A. Jernigan, MD, MS Division.
Surveillance report Annual Epidemiological Report on communicable diseases in Europe ECDC Surveillance Unit European Centre for Disease Prevention and.
Epidemiology and Control of Methicillin-Resistant Staphylococcus aureus in hospitals Maria Kapi,MD Registrar of Medical Microbiology Laiko General Hospital.
C-1 Staphylococcus aureus Bacteremia and Endocarditis: A Bad Bug and A New Drug G. Ralph Corey M.D. Professor of Internal Medicine and Infectious Diseases.
About Microbionical About Founded Business idea: Commercialize Seek & Heal™ technology. ACO Läkemedel, Stockholm – pharmaceutical development.
Antibiotic overuse and misuse in long term care Shira Doron, MD Assistant Professor of Medicine Division of Geographic Medicine and Infectious Diseases.
Emerging infections and Health Protection In Scotland Looking to the future Kirsty Roy and Martin Donaghy Health Protection Scotland Scottish Government.
Hans Wolf-Watz, professor, UCMR, MIMS, Department of Microbiology, Umeå University, Sweden, Antibiotic resistance a new.
Key Strategies for Improving Use of Existing and New Antibiotics -the European Experience Otto Cars Professor Inf. Diseases, Uppsala University, Sweden.
World TB Day By: Adam Brockest, Meg Reid, Michael Kerr & Jason Saxe.
Shira Doron, MD Assistant Professor of Medicine
BACTERIA, ANTIBIOTICS AND ANTIBIOTIC RESISTANCE Photo: Mycobacterium tuberculosis bacteria, NIAID (from flickr). 1 Photo: Staphylococcus epidermidis bacteria,
Ecdc.europa.eu Tommi Asikainen, Tubingen, 22 October 2008 European Centre for Disease Prevention and Control FUTURE DISEASE CHALLENGES IN EUROPE – where.
Sanghyuk Shin, PhD Department of Epidemiology UCLA Fielding School of Public Health Aug 27, 2015 Tuberculosis and HIV Co-infection: “A Deadly Syndemic”
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD: a public health approach to innovation Hans V. Hogerzeil Director, Medicines Policy and Standards WHO, Geneva.
IDO-Staph: An Ontology of Staphylococcus aureus Infectious Disease Albert Goldfain, Ph.D. Researcher, Blue Highway, Inc. Problems.
ECDC-EMEA Joint Technical Report Part I: Trends and burden of antimicrobial resistance in the European Union Zsuzsanna Jakab, Director European Centre.
Measuring Technical Progress and Potential Impact in Real Time Presented at the American Evaluation Association Conference 2009 by Jerald Hage, Wilbur.
The role of the English Surveillance Programme on Antimicrobial Use & Resistance in improving stewardship Susan Hopkins Consultant Infectious Diseases.
Alexandra Heumber Médecins Sans Frontières Access to Essential Medicines Campaign DEBRIEFING WHA May 2006.
1 Combating Drug Resistance Syed Khalid Saeed Bukhari.
EC actions against the rising threats from Antimicrobial Resistance
Antimicrobial resistance
Swedish TV-production on Antibiotic Resistance Financially supported by the EU commission.
Health Statistics and Informatics Non-communicable diseases A global overview.
Evolution of Bacteria Joshua Jackson 2 nd Period Biology Honors.
The Efficacy of Topical Manuka Honey and Combination Antibiotic Therapy in the Treatment of MRSA Skin Infections Kyle Liban Pacific University School of.
Antibiotic Resistance Workshop. Antibiotic resistance – a problem in the present and the future Antibiotic resistance is an increasingly serious public.
Objectives Describe: Antibiotic resistance High priority resistant organisms in long term care settings Key strategies for combating antibiotic resistance.
Research on Antimicrobial Resistance
Antibiotics: handle with care!
Professor Alan Johnson Department of HCAI & AMR
Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.
G. Cornaglia, A. Lönnroth, M. Struelens 
Improving Antibiotic use through a Nationwide Decentralized Project –
The HIV Epidemic among People who Inject Drugs
Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm.
The need for new antibiotics
A. Oliver, A. Mena  Clinical Microbiology and Infection 
Bacterial resistance—the clinical challenge
Strategies for managing today's infections
Access to Medicines: NCDs & NTDS: INSULIN VS PRAZIQUANTEL
Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic.
Can β-lactams be re-engineered to beat MRSA?
Antimicrobial drug development – the past, the present, and the future
G.M. Rossolini, E. Mantengoli  Clinical Microbiology and Infection 
Антибиотикийн тэсвэржилт- дэлхий нийтийн тулгамдсан асуудал
G.C. Schito  Clinical Microbiology and Infection 
Margaret Duguid B Pharm
Presentation transcript:

Antibiotics have saved millions of lives Antibiotics are losing their effect

Global mortality in infectious diseases (WHO estimates for 2002, from World Health Report 2004)

The Rise of Antibacterial Resistance and the Decline in Innovation The proportion (%) of MRSA among positive blood cultures of Staphylococcus aureus in The proportion (%) of MRSA among positive blood cultures of Staphylococcus aureus in England &Wales Antibacterial new molecular entities approved for use in the United States From Kaplan, Laing et al., Priority medicines for Europe and the world, 2004

Increased knowledge on an increasing problem number of hits in Pub-MED for (antibiotic or antimicrobial) + resistance by 5 year’s periods

Seminar on the Global Threat of Antibiotic Resistance Exploring Roads towards Concerted Action Uppsala 5-7 May, 2004 Seminar on the Global Threat of Antibiotic Resistance Exploring Roads towards Concerted Action Uppsala 5-7 May,

Since May 2004…. The clusters –Communicating the message –Ensuring appropriate use –Ensuring supply of new antibiotics Some outcomes –Website ( –WHA resolution –Priority medicines –Innovation study –Network broadened

Current and future generations of people around the globe should have access to effective treatment of bacterial infections.

Will we respond to antibiotic resistance in time? A seminar on the growing threat of antibiotic resistance September 14-17, 2005, Uppsala

The way forward? >2

Will we React in time?